Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

STARTRK-2 (Solid Tumors) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if the study drug (entrectinib) is safe and will work in patients with advanced cancer with a gene mutation.
What is the Condition Being Studied?
Solid tumor cancer with specific gene mutations

Who Can Participate in the Study?

Adults diagnosed with solid tumor cancer that has a gene mutation (NTRK1/2/3, ROS1, or ALK gene rearrangement).

Age Group

What is Involved?

If you choose to be in this study you will:
- Have blood drawn, and a possible tumor tissue biopsy
- Physical and eye exam
- Complete quality of life surveys
- Take study drug (entrectinib) by mouth every day
- Take part in this study until your disease worsens or your study doctor requests you to stop

Study Details

Full Title
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00078723
NCT: NCT02568267
Phase II
Contact the Duke Recruitment Innovation Center